Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Obinutuzumab + Bendamustine in Relapsed/Refractory CLL
2013-003388-79Phase 2Completed
- Sponsor
- Roche Farma, S.A.
- Start
- Dec 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab and bendamustine in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Roche Farma, S.A. Primary endpoints: Overall response rate and Best response rate. Started Dec 2013; status: completed.
02
Drugs
obinutuzumabbendamustine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2013-003388-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003388-79.